<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015244</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03005-50</org_study_id>
    <nct_id>NCT05015244</nct_id>
  </id_info>
  <brief_title>Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease</brief_title>
  <acronym>Von2B</acronym>
  <official_title>Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The working hypothesis is that patients with Von Willebrand Disease-type 2B may have&#xD;
      neurological symptoms due to the chronic formation of platelets/Von Willebrand Factor&#xD;
      aggregates. Interestingly, several patients present nonspecific neurological symptoms&#xD;
      (nystagmus, headaches, memory disorder, â€¦) which may be associated with cerebral&#xD;
      microangiopathy and chronic microvessel inflammation secondary to Von Willebrand Disease-type&#xD;
      2B due to chronic exposure to Von Willebrand Factor-platelets complexes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigator will use an extensive series of neuropsychological tests that cover virtually&#xD;
      all cognitive domains. A measurement of global cognitive function will be assessed by the&#xD;
      Mini Mental State Examination (MMSE). The verbal memory function will be assessed by the Rey&#xD;
      Auditory Verbal Learning Test (RAVLT). Visuospatial memory will be administered by the Rey's&#xD;
      Complex Figure Test (RCFT). To evaluate speed of mental processes, Stroop test (three&#xD;
      subtasks), the Paper and Pencil Memory Scanning Task (four subtasks), the Symbol-Digit&#xD;
      Substitution Task will be used. To evaluate attention, the verbal series attention test&#xD;
      (VSAT) will be used. To register subjective cognitive failures investigator will administer&#xD;
      the Cognitive failures questionnaire (CFQ). The neurological evaluation will be completed&#xD;
      with 3T (Tesla) Magnetic Resonance Imaging (MRI) with different MRI sequences including T1 3D&#xD;
      SPACE, FLAIR 3D , 3D SWI (Susceptibility weighted imaging) and 2D EPI (Echo Planar Imaging)&#xD;
      to address the presence of cerebral small vessel disease. The presence of each of the four&#xD;
      MRI markers for cerebral small vessel disease (white matter hyperintensities, lacunes,&#xD;
      cerebral microbleeds and perivascular spaces will be addressed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of cerebral lesions in patients with type 2B disease</measure>
    <time_frame>at the inclusion</time_frame>
    <description>Analysis of MRI sequences and % of patients with cerebral lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global cognitive function evaluation</measure>
    <time_frame>at the inclusion</time_frame>
    <description>Mini Mental State Examination (MMSE) will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal memory function evaluation</measure>
    <time_frame>at the inclusion</time_frame>
    <description>Rey Auditory Verbal Learning Test (RAVLT) will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visuospatial memory evaluation</measure>
    <time_frame>at the inclusion</time_frame>
    <description>Rey's Complex Figure Test (RCFT) will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speed of mental processes evaluation</measure>
    <time_frame>at the inclusion</time_frame>
    <description>Stroop test will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention evaluation</measure>
    <time_frame>at the inclusion</time_frame>
    <description>Verbal series attention test (VSAT) will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective cognitive failures evaluation</measure>
    <time_frame>at the inclusion</time_frame>
    <description>Cognitive failures questionnaire (CFQ) will be used</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Von Willebrand Disease, Type 2B</condition>
  <arm_group>
    <arm_group_label>Von Willebrand Disease Type 2B patient with neurological symptoms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>evaluation of patients using 3T (Tesla) Magnetic Resonance Imaging (MRI) and series of neuropsychological tests that cover virtually all cognitive domains.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>3T (Tesla) Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Neurological evaluation using MRI and neuropsychological tests</description>
    <arm_group_label>Von Willebrand Disease Type 2B patient with neurological symptoms</arm_group_label>
    <other_name>Series of neuropsychological tests that cover virtually all cognitive domains</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with type 2B disease&#xD;
&#xD;
          -  neurological signs&#xD;
&#xD;
          -  signature of inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication for MRI&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  other hemorrhagic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic VARNIER</last_name>
      <phone>0231063106</phone>
      <phone_ext>+33</phone_ext>
      <email>directiongenerale@chu-caen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Caen</investigator_affiliation>
    <investigator_full_name>Yohann REPESSE</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>VWF</keyword>
  <keyword>Type 2B von willebrand disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
    <mesh_term>Von Willebrand Disease, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

